{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T11:18:28Z","timestamp":1761218308137,"version":"build-2065373602"},"reference-count":38,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2020,11,28]],"date-time":"2020-11-28T00:00:00Z","timestamp":1606521600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Therapies for HCV care could change the prevalence and the geographic distribution of genotypes due to differences in Sustained Virologic Response (SVR). In this scenario, uncommon genotypes\/subtypes, such as genotype 4, could spread from high-risk groups, replacing genotypes eradicated by antiviral drugs. Genotype eradication is also strongly influenced by the CD8+ T cell response. In this study, the genetic variability in HCV genotype 4 strains obtained from a cohort of 67 patients na\u00efve to DAA therapy was evaluated. We found that the presence of resistance-associated substitutions (RAS) was able to affect drug responses. Next, using a prediction tool, viral mutations were identified by their ability, or lack thereof, to reduce the binding affinity with HLA, which affects T cell recognition. The Bayesian coalescent analysis suggested two different circulation clusters, one in risk groups (IDUs and MSM) and the other due to migration flows, dated to 1940 and 1915, respectively. Most of the RAS overlapped with HLA and a lack of binding mutations was observed in 96% of strains. This study describes the introduction of HCV genotype 4 in a region of the Mediterranean basin and evaluates how HCV genotype 4\u2019s genetic variability could affect the response of antiviral drugs and CD8+ T cell recognition.<\/jats:p>","DOI":"10.3390\/v12121363","type":"journal-article","created":{"date-parts":[[2020,11,29]],"date-time":"2020-11-29T21:00:57Z","timestamp":1606683657000},"page":"1363","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Phylodynamic Analysis and Implication of HCV Genotype 4 Variability on Antiviral Drug Response and T-Cell Recognition"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0465-5445","authenticated-orcid":false,"given":"Giuseppina Maria Elena","family":"Colomba","sequence":"first","affiliation":[{"name":"Dipartimento di Scienze per la Promozione della Salute, Materno-Infantile di Medicina Interna e Specialistica di Eccellenza \u201cG. D\u2019Alessandro\u201d, 90133 Palermo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noemi","family":"Urone","sequence":"additional","affiliation":[{"name":"Dipartimento di Scienze per la Promozione della Salute, Materno-Infantile di Medicina Interna e Specialistica di Eccellenza \u201cG. D\u2019Alessandro\u201d, 90133 Palermo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vito di","family":"Marco","sequence":"additional","affiliation":[{"name":"Dipartimento di Scienze per la Promozione della Salute, Materno-Infantile di Medicina Interna e Specialistica di Eccellenza \u201cG. D\u2019Alessandro\u201d, 90133 Palermo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donatella","family":"Ferraro","sequence":"additional","affiliation":[{"name":"Dipartimento di Scienze per la Promozione della Salute, Materno-Infantile di Medicina Interna e Specialistica di Eccellenza \u201cG. D\u2019Alessandro\u201d, 90133 Palermo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,11,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ijid.2005.07.008","article-title":"Distribution of hepatitis C virus genotypes in the Middle East","volume":"10","author":"Ramia","year":"2006","journal-title":"Int. J. Infect. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/hep.27259","article-title":"Global distribution and prevalence of hepatitis C virus genotypes","volume":"61","author":"Messina","year":"2015","journal-title":"Hepatology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1016\/j.jhep.2014.07.027","article-title":"Global epidemiology and genotype distribution of the hepatitis C virus infection","volume":"61","author":"Gower","year":"2014","journal-title":"J. Hepatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S0140-6736(99)06527-7","article-title":"The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt","volume":"11","author":"Frank","year":"2000","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/j.1365-2893.2005.00605.x","article-title":"Changing of hepatitis C virus genotype patterns in France at the beginning of the third millenium: The GEMHEP GenoCII Study","volume":"12","author":"Payan","year":"2005","journal-title":"J. Viral. Hepat."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1365-2893.2005.00649.x","article-title":"Molecular epidemiology of hepatitis C virus (HCV) in Greece: Temporal trends in HCV genotype-specific incidence and molecular characterization of genotype 4 isolates","volume":"13","author":"Katsoulidou","year":"2006","journal-title":"J. Viral. Hepat."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jhep.2007.07.033","article-title":"The changing epidemiology of hepatitis C virus infection in Europe","volume":"48","author":"Esteban","year":"2008","journal-title":"J. Hepatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1002\/jmv.23384","article-title":"Hepatitis C virus genotype 4d in Southern Italy: Reconstruction of its origin and spread by a phylodynamic analysis","volume":"10","author":"Ciccozzi","year":"2012","journal-title":"J. Med. Virol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1002\/jmv.21498","article-title":"HCV genotypes in Sicily: Is there any evidence of a shift?","volume":"81","author":"Pizzillo","year":"2009","journal-title":"J. Med. Virol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1002\/jmv.21276","article-title":"Phylogenetic reconstruction of HCV genotype 1b dissemination in a small city centre: The Camporeale model","volume":"80","author":"Ferraro","year":"2008","journal-title":"J. Med. Virol."},{"key":"ref_11","unstructured":"(2020, November 28). EASL Guidelines. Available online: http:\/\/www.easl.eu."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"5550","DOI":"10.1128\/JVI.75.12.5550-5558.2001","article-title":"Sustained dysfunction of antiviral CD8+ T lymphocytes after infection with hepatitis C virus","volume":"75","author":"Gruener","year":"2001","journal-title":"J. Virol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1086\/380821","article-title":"Spread of hepatitis C virus among European injection drug users infected with HIV: a phylogenetic analysis","volume":"189","author":"Verhaest","year":"2004","journal-title":"J. Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/1471-2148-7-214","article-title":"BEAST: Bayesian evolutionary analysis by sampling trees","volume":"7","author":"Drummond","year":"2007","journal-title":"BMC Evol. Biol."},{"key":"ref_15","unstructured":"(2020, November 28). HCV Databases, Available online: http:\/\/hcv.lanl.gov."},{"key":"ref_16","unstructured":"(2020, November 28). Datamonkey Adaptative Evolution Server. Available online: https:\/\/www.datamonkey.org\/."},{"key":"ref_17","unstructured":"(2020, November 28). Genafor\u2014Open Service for Medical Research. Available online: http:\/\/hcv.geno2pheno.org\/index.php."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1002\/hep.27934","article-title":"Hepatitis C virus drug resistance-associated substitutions: State of the art summary","volume":"5","author":"Lontok","year":"2015","journal-title":"Hepatology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1053\/j.gastro.2016.04.003","article-title":"Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in Interferon-Free Regimens","volume":"1","author":"Pawlotsky","year":"2016","journal-title":"Gastroenterology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/jvh.12614","article-title":"Virology analyses of HCV genotype 4 isolates from patients treated with simeprevir and peginterferon\/ribavirin in the Phase III RESTORE study","volume":"24","author":"Fevery","year":"2017","journal-title":"J. Viral. Hepat."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jcv.2015.02.001","article-title":"Dynamics of HCV genotype 4 resistance-associated variants during virologic escape with pIFN\/RBV+daclatasvir: A case study using ultra deep pyrosequencing","volume":"66","author":"Bartolini","year":"2015","journal-title":"J. Clin. Virol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1097\/01.qai.0000209899.05126.e4","article-title":"The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes","volume":"41","author":"Wensing","year":"2006","journal-title":"J. Acquir. Immune. Defic. Syndr."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.meegid.2014.01.028","article-title":"HCV-1b intra-subtype variability: Impact on genetic barrier to protease inhibitors","volume":"23","author":"Ferraro","year":"2014","journal-title":"Infect. Genet. Evol."},{"key":"ref_24","unstructured":"(2020, November 28). Free Epitopes Database and Prediction Resources. Available online: https:\/\/www.iedb.org\/."},{"key":"ref_25","unstructured":"(2020, November 28). Allele Frequency Net Database. Available online: http:\/\/www.allelefrequencies.net\/."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1110\/ps.0239403","article-title":"Reliable prediction of T-cell epitopes using neural networks with novel sequence representations","volume":"12","author":"Nielsen","year":"2003","journal-title":"Protein. Sci."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"6807","DOI":"10.1128\/AAC.01229-15","article-title":"Hepatitis C virus genotype 4 resistance and subtype demographic characterization of patients treated with ombitasvir plus paritaprevir\/ritonavir","volume":"59","author":"Schnell","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1186\/1471-2334-14-S5-S2","article-title":"Update on epidemiology of HCV in Italy: Focus on the Calabria Region","volume":"14","author":"Marascio","year":"2014","journal-title":"BMC Infect. Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.meegid.2004.08.001","article-title":"The hepatitis C virus epidemic among injecting drug users","volume":"2","author":"Pybus","year":"2005","journal-title":"Infect. Genet. Evol."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Rajhi, M., and Ghedira, K. (2016). Phylogenetic Analysis and Epidemic History of Hepatitis C Virus Genotype 2 in Tunisia, North Africa. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0153761"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1093\/infdis\/jiv379","article-title":"NS5A Sequence Heterogeneity and Mechanisms of Daclatasvir Resistance in Hepatitis C Virus Genotype 4 Infection","volume":"213","author":"Zhou","year":"2016","journal-title":"J. Infect. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3852126","DOI":"10.1155\/2016\/3852126","article-title":"Elbasvir\/Grazoprevir: A Review of the Latest Agent in the Fight against Hepatitis C","volume":"2016","author":"Bell","year":"2016","journal-title":"Int. J. Hepatol."},{"key":"ref_33","first-page":"37","article-title":"A cellular replicon-based phenotyping assay to determine susceptibility of hepatitis C virus clinical isolates to NS3\/4A protease inhibitors","volume":"2","author":"Vijgen","year":"2013","journal-title":"Methods. Mol. Biol."},{"key":"ref_34","first-page":"173","article-title":"In Vitro Susceptibility of Hepatitis C Virus Genotype 1 through 6 Clinical Isolates to the Pangenotypic NS3\/4A Inhibitor Voxilaprevir","volume":"57","author":"Bin","year":"2020","journal-title":"J. Clin. Microbiol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jhep.2011.01.011","article-title":"Hepatitis C virus resistance to protease inhibitors","volume":"55","author":"Halfon","year":"2011","journal-title":"J. Hepatol."},{"key":"ref_36","first-page":"21","article-title":"Retreatment of Hepatitis C Virus-Infected Patients with Direct-Acting Antiviral Failures","volume":"38","author":"Pawlotsky","year":"2016","journal-title":"Int. J. Hepatol."},{"key":"ref_37","unstructured":"(2019). Computational analysis of naturally occurring resistance-associated substitutions in genes NS3, NS5A, and NS5B among 86 subtypes of hepatitis C virus worldwide. Infect. Drug. Resist., 8, 17\u201323."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1002\/hep.22773","article-title":"Hepatitis C virus drug resistance and immune-driven adaptations: Relevance to new antiviral therapy","volume":"49","author":"Gaudieri","year":"2009","journal-title":"Hepatology"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/12\/12\/1363\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:38:59Z","timestamp":1760179139000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/12\/12\/1363"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,28]]},"references-count":38,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["v12121363"],"URL":"https:\/\/doi.org\/10.3390\/v12121363","relation":{},"ISSN":["1999-4915"],"issn-type":[{"type":"electronic","value":"1999-4915"}],"subject":[],"published":{"date-parts":[[2020,11,28]]}}}